Current and Emerging Therapeutic Strategies in Pancreatic Cancer: Challenges and Opportunities

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2021 Nov 10

PMID 34754153

Citations 12

Authors

Manish Manrai

T V S V G K Tilak

Saurabh Dawra

Sharad Srivastava

Anupam Singh

Affiliations

Soon will be listed here.

Abstract

Pancreatic carcinoma (PC) is one of the leading causes of cancer-related deaths worldwide. Despite early detection and advances in therapeutics, the prognosis remains dismal. The outcome and therapeutic approach are dependent on the stage of PC at the time of diagnosis. The standard of care is surgery, followed by adjuvant chemotherapy. The advent of newer drugs has changed the landscape of adjuvant therapy. Moreover, recent trials have highlighted the role of neoadjuvant therapy and chemoradiotherapy for resectable and borderline resectable PC. As we progress towards a better understanding of tumor biology, genetics, and microenvironment, novel therapeutic strategies and targeted agents are now on the horizon. We have described the current and emerging therapeutic strategies in PC.

Citing Articles

Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes.

Zhang X, Lan R, Liu Y, Pillarisetty V, Li D, Zhao C NPJ Precis Oncol. 2025; 9(1):58.

PMID: 40032924 PMC: 11876354. DOI: 10.1038/s41698-025-00848-2.

Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review.

Hayat U, Croce P, Saadeh A, Desai K, Appiah J, Khan S J Clin Med. 2025; 14(4).

PMID: 40004658 PMC: 11856716. DOI: 10.3390/jcm14041129.

Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: a qualitative phenomenological study in Southwest China.

Chen P, Hou W, Li C, Liang Q, Ma L, Zhao X BMJ Open. 2025; 15(1):e084259.

PMID: 39880447 PMC: 11781101. DOI: 10.1136/bmjopen-2024-084259.

Prediction of 12-month recurrence of pancreatic cancer using machine learning and prognostic factors.

Nopour R BMC Med Inform Decis Mak. 2024; 24(1):339.

PMID: 39543603 PMC: 11566389. DOI: 10.1186/s12911-024-02766-y.

Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal Adenocarcinoma.

Zhang X, Lan R, Liu Y, Pillarisetty V, Li D, Zhao C Res Sq. 2024; .

PMID: 38798691 PMC: 11118688. DOI: 10.21203/rs.3.rs-4104258/v1.

References

Van Der Gaag N, Rauws E, van Eijck C, Bruno M, van der Harst E, Kubben F . Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010; 362(2):129-37. DOI: 10.1056/NEJMoa0903230. View

Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H . A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer. 2008; 113(9):2448-56. DOI: 10.1002/cncr.23863. View

. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987; 59(12):2006-10. DOI: 10.1002/1097-0142(19870615)59:12<2006::aid-cncr2820591206>3.0.co;2-b. View

Negoi I, Hostiuc S, Runcanu A, Negoi R, Beuran M . Superior mesenteric artery first approach versus standard pancreaticoduodenectomy: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int. 2017; 16(2):127-138. DOI: 10.1016/s1499-3872(16)60134-0. View

Klinkenbijl J, Jeekel J, Sahmoud T, van Pel R, Couvreur M, Veenhof C . Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 2000; 230(6):776-82; discussion 782-4. PMC: 1420941. DOI: 10.1097/00000658-199912000-00006. View

Janssen Q, Buettner S, Suker M, Beumer B, Addeo P, Bachellier P . Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019; 111(8):782-794. PMC: 6695305. DOI: 10.1093/jnci/djz073. View

Sehdev A, Gbolahan O, Hancock B, Stanley M, Shahda S, Wan J . Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clin Cancer Res. 2018; 24(24):6204-6211. DOI: 10.1158/1078-0432.CCR-18-1472. View

Wang C, Liu X, Wang X, Wang Y, Cha N . Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018; 97(36):e12260. PMC: 6133448. DOI: 10.1097/MD.0000000000012260. View

Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-81. DOI: 10.1001/jama.2013.279201. View

10.

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

11.

Perinel J, Adham M . Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol. 2019; 4:28. PMC: 6556680. DOI: 10.21037/tgh.2019.04.03. View

12.

Lai E, Tang C . Robot-assisted laparoscopic hepaticojejunostomy for advanced malignant biliary obstruction. Asian J Surg. 2015; 38(4):210-3. DOI: 10.1016/j.asjsur.2015.01.010. View

13.

Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H . Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28(22):3617-22. PMC: 2917317. DOI: 10.1200/JCO.2010.28.1386. View

14.

Neuzillet C, Gaujoux S, Williet N, Bachet J, Bauguion L, Colson Durand L . Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis. 2018; 50(12):1257-1271. DOI: 10.1016/j.dld.2018.08.008. View

15.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

16.

Schorn S, Demir I, Reyes C, Saricaoglu C, Samm N, Schirren R . The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev. 2017; 55:96-106. DOI: 10.1016/j.ctrv.2017.03.003. View

17.

Portal A, Pernot S, Tougeron D, Arbaud C, Thirot Bidault A, De La Fouchardiere C . Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015; 113(7):989-95. PMC: 4651133. DOI: 10.1038/bjc.2015.328. View

18.

Hsieh M, Chang W, Yu H, Lu C, Chang C, Chow J . Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018; 7(6):2328-2338. PMC: 6010773. DOI: 10.1002/cam4.1479. View

19.

Moore K . Endothelin and vascular function in liver disease. Gut. 2004; 53(2):159-61. PMC: 1774918. DOI: 10.1136/gut.2003.024703. View

20.

Kang H, Jo J, Lee H, Chung M, Bang S, Park S . Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018; 10(11):421-430. PMC: 6247105. DOI: 10.4251/wjgo.v10.i11.421. View